Overexpression of the lncRNA FER1L4 inhibits paclitaxel tolerance of ovarian cancer cells via the regulation of the MAPK signaling pathway

Liu, Siwei; Zou, Bingyu; Tian, Tian; Luo, Xiaohui; Mao, Banyun; Zhang, Xun; Lei, Huajiang

doi:10.1002/jcb.28032

Cited by 38 publications

(24 citation statements)

References 39 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early to 2015, it was reported that high level expression of HOTAIR could induce platinum resistance in ovarian cancer cells by DNA methylation [24]. In addition, researchers found over-expression of lncRNA-FER1L4 could increase the sensitivity of ovarian cancer cells to paclitaxel by inhibiting MAPK signaling pathways [25]. Also, lncRNA-KB-1471A8.2 was reported to be down-regulated in ovarian cancer tissues and chemo-resistant ovarian cancer cells and could act as tumor-suppressor gene by inhibiting the expression of CDK4 [26].…”

Section: Discussionmentioning

confidence: 99%

Dys-regulation of Lnc-SNHG1 and miR-216b-5p Correlate With Chemo-resistance and Indicate Poor Prognosis of Serous Epithelial Ovarian Cancer

Pei

Zhao

Shuang

2020

Preprint

View full text Add to dashboard Cite

Background: Ovarian cancer is the most lethal of gynecological cancers and the 5-year survival rate is still low and chemo-resistance is the main obstacle for the treatment of ovarian cancer. Methods and Results: In this study, the human ovarian cancer tissue microarray was applied, 63 cases of chemo-sensitive serous EOC tissues and 32 cases of chemo-resistant serous EOC tissues were selected. By applying RNA fluorescence in situ hybridization (FISH), we found expression of Lnc-SNHG1 was up-regulated while miR-216b-5p showed low expression in chemo-resistant EOC patients compared with the chemo-sensitive group, both were mainly localized in the cytoplasm of the tissue cells. Chi-square test showed high lnc-SNHG1 level was significantly correlated with tumor stage, histological grade, nodal status, metastasis and chemo-resistance except tumor size. While there was no significant association between miR-216b-5p expression and parameters including tumor stage, histological grade, nodal status, metastasis, except chemo-resistance (P=0.0001). Spearman’s correlation analysis revealed significantly negative correlations between lnc-SNHG1 and miR-216b-5p (r = -0.424, P = 0.0001). Multivariate Cox regression analysis showed the expression of miR-216b-5p (P = 0.012, RR 2.137, 95 % CI 1.109–5.339) and FIGO stage (P = 0.001, RR 3.537, 95 % CI 1.72–7.276) was independent prognostic factors for the overall survival (OS) of serous EOC patients .While the FIGO stage (P = 0.003, RR2.237, 95 % CI 1.323–3.783) was the independent prognostic factor for the disease free survival (DFS) for the serous EOC patients. Kaplan- Meier curves revealed significant association of increased expression of lnc-SNHG1 with less OS and shorter DFS, while patients with low level of miR-216b-5p indicated less OS and DFS. Conclusions: In a word, we claimed over-expression of lnc-SNHG1 and decreased expression of miR-216b-5p were correlated with chemo-resistance of serous EOC patients and indicated less OS and shorter DFS of the patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Dys-regulation of Lnc-SNHG1 and miR-216b-5p Correlate With Chemo-resistance and Indicate Poor Prognosis of Serous Epithelial Ovarian Cancer

Pei

Zhao

Shuang

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Besides, miR‐128 inhibited the invasion and modulates chemosensitivity of prostate cancer cells to cisplatin, suggesting that miR‐128 functions as a rational therapeutic strategy for prostate cancer . Paclitaxel is a natural anti‐tumour agent that widely used for the treatment of a variety of tumours, including ovarian cancer . Koh et al reported that miR‐128 suppressed cell proliferation, metastasis, self‐renewal, migration and invasive ability of paclitaxel‐resistant lung cancer stem cells via inhibiting BMI‐1 proto‐oncogene, polycomb ring finger (BMI‐1) and C‐terminal Mucin1 (MUC1‐C).…”

Section: Discussionmentioning

confidence: 99%

“…26 Paclitaxel is a natural anti-tumour agent that widely used for the treatment of a variety of tumours, including ovarian cancer. 27 Koh et al 13 reported that miR-128 suppressed cell proliferation, metastasis, self-renewal, migration and invasive ability of paclitaxel-resistant lung cancer stem cells via inhibiting BMI-1 proto-oncogene, polycomb ring finger (BMI-1) and C-terminal Mucin1 (MUC1-C). A previous study showed that miR-128 level was decreased in cisplatin-resistant epithelial ovarian cancer SKOV-3/CP cells compared with that in parental SKOV-3 cells, and miR-128 overexpression suppressed cisplatin resistance in SKOV-3/CP cells.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA‐128/homeobox B8 axis regulates ovarian cancer cell progression

Gong

Пин

et al. 2019

Basic Clin Pharma Tox

View full text Add to dashboard Cite

MicroRNA‐128 (miR‐128) has been found to be dysregulated and might function as a tumour suppressor in various cancers, including ovarian cancer. However, the underlying mechanism of miR‐128 in ovarian cancer has not been fully understood. The miR‐128 and homeobox B8 (HOXB8) levels in clinical samples and cultured cell lines were measured using qRT‐PCR and/or Western blot analysis. Cell proliferation was assessed using Cell Counting Kit‐8 assay. Cell apoptosis was determined using flow cytometry. The association between miR‐128 and HOXB8 was confirmed using dual‐luciferase reporter assay. Results showed that decreased miR‐128 expression and increased HOXB8 expression were observed in ovarian cancer tissues and cell lines. Transfection with miR‐128 mimics suppressed the cell proliferation and enhanced paclitaxel sensitivity in ovarian cancer cell lines. miR‐128 directly targeted HOXB8 in ovarian cancer cell lines. Knockdown of HOXB8 abolished the effects of miR‐128 inhibitor on ovarian cancer cell proliferation and paclitaxel sensitivity. Summarily, miR‐128 displayed a tumour suppressor role in ovarian cancer via targeting HOXB8. It is supposed that miR‐128 might be effective for targeting therapy for ovarian cancer.

show abstract

“…In OC, FER1L4 is expressed at low levels compared to normal ovarian epithelial cells and, at even lower levels in paclitaxel-resistant cell lines. Transfection with FER1L4 led to MAPK pathway suppression and restored the sensitivity to paclitaxel, indicating an important role in the development of resistance (177). Overall, PTEN-AKT-mTOR and MAPK are major cancer driver pathways deeply…”

Section: Lncrnas Involved In the Taxane Resistancementioning

confidence: 96%

Long Non-coding RNAs Involved in Resistance to Chemotherapy in Ovarian Cancer

et al. 2020

View full text Add to dashboard Cite

Ovarian cancer (OC) accounts for more than 150,000 deaths worldwide every year. Patients are often diagnosed at an advanced stage with metastatic dissemination. Although platinum-and taxane-based chemotherapies are effective treatment options, they are rarely curative and eventually, the disease will progress due to acquired resistance. Emerging evidence suggests a crucial role of long non-coding RNAs (lncRNAs) in the response to therapy in OC. Transcriptome profiling studies using high throughput approaches have identified differential expression patterns of lncRNAs associated with disease recurrence. Furthermore, several aberrantly expressed lncRNAs in resistant OC cells have been related to increased cell division, improved DNA repair, up-regulation of drug transporters or reduced susceptibility to apoptotic stimuli, supporting their involvement in acquired resistance. In this review, we will discuss the key aspects of lncRNAs associated with the development of resistance to platinum-and taxane-based chemotherapy in OC. The molecular landscape of OC will be introduced, to provide a background for understanding the role of lncRNAs in the acquisition of malignant properties. We will focus on the interplay between lncRNAs and molecular pathways affecting drug response to evaluate their impact on treatment resistance. Additionally, we will discuss the prospects of using lncRNAs as biomarkers or targets for precision medicine in OC. Although there is still plenty to learn about lncRNAs and technical challenges to be solved, the evidence of their involvement in OC and the development of acquired resistance are compelling and warrant further investigation for clinical applications.

show abstract

Overexpression of the lncRNA FER1L4 inhibits paclitaxel tolerance of ovarian cancer cells via the regulation of the MAPK signaling pathway

Cited by 38 publications

References 39 publications

Dys-regulation of Lnc-SNHG1 and miR-216b-5p Correlate With Chemo-resistance and Indicate Poor Prognosis of Serous Epithelial Ovarian Cancer

Dys-regulation of Lnc-SNHG1 and miR-216b-5p Correlate With Chemo-resistance and Indicate Poor Prognosis of Serous Epithelial Ovarian Cancer

MicroRNA‐128/homeobox B8 axis regulates ovarian cancer cell progression

Long Non-coding RNAs Involved in Resistance to Chemotherapy in Ovarian Cancer

Contact Info

Product

Resources

About